Ocular Therapeutix (OCUL) Invested Capital (2013 - 2026)

Ocular Therapeutix has reported Invested Capital for 14 years, with the latest figure at $581.6 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 118.69% year-over-year to $581.6 million; the trailing twelve-month figure through Mar 2026 stood at $581.6 million (up 118.69% YoY), and the FY2025 full-year result was $654.3 million, up 107.49% from the prior year.
• Invested Capital for Q1 2026 stood at $581.6 million, down from $654.3 million in the prior quarter.
• The five-year high for Invested Capital was $654.3 million in Q4 2025, with the low at $3.1 million in Q2 2023.
• Average Invested Capital over 5 years is $234.3 million, with a median of $258.2 million recorded in 2025.
• Year-over-year, Invested Capital plunged 95.31% in 2023 and jumped 12135.02% in 2024.
• Tracing OCUL's Invested Capital over 5 years: stood at $72.9 million in 2022, then jumped by 76.49% to $128.6 million in 2023, then surged by 145.15% to $315.3 million in 2024, then soared by 107.49% to $654.3 million in 2025, then retreated by 11.12% to $581.6 million in 2026.
• The last three Invested Capital figures came in at $581.6 million (Q1 2026), $654.3 million (Q4 2025), and $258.2 million (Q3 2025), per Business Quant data.

Peer Comparison